Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$82,955.00+1.26%ETH$2,447.96+1.73%GOLD$4,134.20-0.20%OIL$98.38+0.57%
Smart Investors Daily
SID Premium
PH

NASDAQ · PHAT

Phathom Pharmaceuticals, Inc.

Healthcare · Biotechnology

$7.01

Up+$0.30 (+4.28%)

Updated Oct 20, 2026, 11:14 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.04B
P/E ratio
-3.89
Dividend yield
0.00%
52-week range
$6.52 – $18.31
Volume
1.02M
Avg. volume
1.06M

Price performance · PHAT

PHAT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 19, 2026

PHAT closed at $7.01 after 21 trading sessions, down 5.91% for the selected period.

Last close
$7.01
Period change
-5.91%
Period low
$6.70
Period high
$7.76
Daily close
View OHLC price history
PHAT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 19, 2026$6.88$7.05$6.78$7.011.02M
Oct 16, 2026$7.51$7.5699$6.90$6.921.25M
Oct 15, 2026$7.54$7.69$7.41$7.501.21M
Oct 14, 2026$6.97$7.72$6.9178$7.401.72M
Oct 13, 2026$7.14$7.16$6.86$7.001.95M
Oct 12, 2026$7.25$7.285$7.03$7.131.01M
Oct 9, 2026$7.13$7.30$7.015$7.25928.34K
Oct 8, 2026$6.79$7.18$6.68$7.131.33M
Oct 7, 2026$6.87$7.03$6.60$6.811.63M
Oct 6, 2026$6.75$6.80$6.52$6.782.09M
Oct 5, 2026$6.95$7.00$6.645$6.701.1M
Oct 2, 2026$7.20$7.23$6.82$6.921.68M
Oct 1, 2026$7.47$7.47$7.08$7.081.06M
Sep 30, 2026$7.40$7.50$7.19$7.30809.2K
Sep 29, 2026$7.34$7.45$7.185$7.36657.26K
Sep 28, 2026$7.30$7.41$7.15$7.351.69M
Sep 25, 2026$7.10$7.38$7.095$7.301.44M
Sep 24, 2026$6.98$7.19$6.91$7.081.42M
Sep 23, 2026$7.825$7.825$6.98$6.9851.05M
Sep 22, 2026$7.58$7.84$7.40$7.761.95M
Sep 21, 2026$7.54$7.62$7.31$7.45898.88K

Latest PHAT news

The latest Smart Investors Daily articles mentioning PHAT.

Stock researchCompany · Overview

PHAT research

Overview

Company profile and research snapshot.

Company profile

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.40
Implied upside
—
Analysts
—
PHAT recent ratings
DateFirmRatingTarget
Sep 9, 2026Leerink PartnersMarket Perform—
Aug 17, 2026BarclaysOverweight—
Jul 31, 2026HC Wainwright & Co.Buy—
Jul 31, 2026GuggenheimBuy—
Jul 30, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream complicationsAdditional Phathom-sponsored data highlight VOQUEZNA treatment effect across BMI subgroups in Non-Erosive GERD and real-world patient characteristicsVonoprazan was also the subject of 38

Yahoo · Oct 8, 2026

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of

Yahoo · Sep 29, 2026

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 dataTopline results expected in the first quarter of 2028pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) a

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By